The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae

Vaccine

Volumn 19, Issue SUPPL. 1, 2000, Pages

  Briles, David E ^a,b,e   Hollingshead, Susan K ^a   Nabors, Gary S ^c   Paton, James C ^d   Brooks Walter, Alexis ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c SANOFI PASTEUR   (France)

^d WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^e NONE   (United States)

Author keywords

PsaA; PspA; Streptococcus pneumoniae

Indexed keywords

BACTERIAL PROTEIN; CHOLERA TOXIN B SUBUNIT; IMMUNOGLOBULIN A1; PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOLYSIN; PROTEIN PSA A; PROTEIN PSP A; PROTEIN PSP C; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL IMMUNITY; BACTERIAL VIRULENCE; BACTERIUM CARRIER; CROSS REACTION; DRUG EFFICACY; INFECTION PREVENTION; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; SYMPTOM;

EID: 0034623905     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00285-1     Document Type: Short Survey

References (34)

1. Pneumoccal infection
2. Haemophilus influenzae type b polysaccharide-protein conjugate vaccines in children
3. Use of conjugate vaccines to prevent meningitis caused by Haemophilus influenzae type b or Streptococcus pneumoniae
4. Six newly recognized types of Streptococcus pneumoniae
5. Carriage of pneumomcocci after pneumococcal vaccination
6. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
7. Immunity to Streptococcus pneumoniae
8. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis
9. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues
10. Antigen-independent selection of T15 idiotype during B-cell ontogeny in mice
11. Pneumococcal diversity: Considerations for new vaccine strategies with an emphasis on pneumococcal surface protein A (PspA)
12. Novel pneumococcal surface proteins: Role in virulence and vaccine potential
13. Vaccine strategies for Streptococcus pneumoniae
14. The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia
15. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection
16. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae
17. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae
18. A comprehensive genetic study of streptococcal immunoglobulin A1 proteases: Evidence for recombination within and between species
19. Effects of active immunization with a pneumococcal surface protein (PspA) and of locally applied antibodies in experimental otitis media
20. Epidemiologic studies of Streptococcus pneumoniae in infants: Acquisition, carriage, and infection during the first 24 months of life
21. Establishment of a Streptococcus pneumoniae nasopharyngeal model of pneumococcal carriage in adult mice
22. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage and infection with Streptococcus pneumoniae
23. Recombinant engineering of PspA antigen from Streptococcus pneumoniae as a Pam3cys-lipidated protein potentiates immunogenicity of both parenteral and mucosal routes of administration
24. PspA, a protection-eliciting pneumococcal protein: Immunogenicity of isolated native PspA in mice
25. Current options for vaccine delivery systems by mucosal routes
26. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant
27. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines
28. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae
29. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antiboides
30. Systemic and mucosal protective immunity to pneumococcal surface protein A
31. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type
32. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice
33. Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types
34. Additive attenuation of virulence of Streptococcus pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins